![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXorf21 |
Gene summary for CXORF21 |
![]() |
Gene information | Species | Human | Gene symbol | CXorf21 | Gene ID | 80231 |
Gene name | TLR adaptor interacting with endolysosomal SLC15A4 | |
Gene Alias | CXorf21 | |
Cytomap | Xp21.2 | |
Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q9HAI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80231 | CXorf21 | HCC1 | Human | Liver | HCC | 2.78e-04 | 8.55e-01 | 0.5336 |
80231 | CXorf21 | HCC2 | Human | Liver | HCC | 1.67e-09 | 8.83e-01 | 0.5341 |
80231 | CXorf21 | HCC5 | Human | Liver | HCC | 1.58e-04 | 4.27e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXorf21 | SNV | Missense_Mutation | c.877N>G | p.Ile293Val | p.I293V | Q9HAI6 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
CXorf21 | SNV | Missense_Mutation | novel | c.748N>A | p.Asp250Asn | p.D250N | Q9HAI6 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CXorf21 | SNV | Missense_Mutation | c.366N>T | p.Lys122Asn | p.K122N | Q9HAI6 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | rs369573227 | c.529N>T | p.Pro177Ser | p.P177S | Q9HAI6 | protein_coding | tolerated(0.71) | benign(0.023) | TCGA-D1-A2G0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.269N>A | p.Pro90His | p.P90H | Q9HAI6 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.803G>T | p.Arg268Ile | p.R268I | Q9HAI6 | protein_coding | deleterious(0) | benign(0.203) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.78G>T | p.Gln26His | p.Q26H | Q9HAI6 | protein_coding | tolerated(0.14) | benign(0.366) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | c.366N>T | p.Lys122Asn | p.K122N | Q9HAI6 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
CXorf21 | SNV | Missense_Mutation | rs751575628 | c.688N>A | p.Val230Met | p.V230M | Q9HAI6 | protein_coding | tolerated(1) | benign(0.006) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.780N>T | p.Lys260Asn | p.K260N | Q9HAI6 | protein_coding | deleterious(0.04) | possibly_damaging(0.719) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |